news – Page 5621 – pharmaceutical daily

March 17, 2017 Off

Five out of nine sectors ended Thursday’s trading session in bullish territories

On Thursday, March 16, 2017, the Dow Jones Industrial Average and the S&P 500 edged 0.07% and 0.16% lower, respectively, at the closing bell, while the NASDAQ Composite stayed bullish, finishing marginally higher by 0.01%. Five out of nine sectors ended Thursday’s trading session in bullish territories. Taking into consideration yesterday’s market sentiment, Stock-Callers.com assessed the several drugs – generic equities on Friday.

March 17, 2017 Off

Roche launches nucleic acid extraction and purification instrument

By Dino Mustafić

Roche has launched a new instrument for nucleic acid extraction and purification, the MagNA Pure 24 System. The new system offers an extraction solution with on-board primary sample handling for low to medium throughput customers who require high quality nucleic acid extractions, said Roche.

March 17, 2017 Off

MRC gives £2.8M to six consortium partners for Rheumatoid Arthritis research

By Dino Mustafić

Oxford BioDynamics is one of six consortium partners to examine and address why immune-mediated inflammatory diseases (IMIDs) remit and relapse, with a particular focus on Rheumatoid Arthritis (RA).

March 17, 2017 Off

AstraZeneca to resolve certain matters related to development of hyperkalameia powder

By Dino Mustafić

AstraZeneca’s subsidiary ZS Pharma has been developing an oral powder as a treatment for high potassium levels in the blood serum, called hyperkalaemia, for which it got a Complete Response Letter (CRL) from the Food and Drug Administration (FDA).

March 17, 2017 Off

Pharnext starts Phase 3 trial for its neuro disease drug

By Dino Mustafić

Pharnext, a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, has enroled the first two patients to the international Phase 3 Extension Study PLEO-CMT-FU of PXT3003 at La Timone University Hospital (Marseille, France).

March 16, 2017 Off

Diplomat gets distribution of Novartis’s new cancer drug

By Dino Mustafić

Diplomat Pharmacy will distribute Novartis’s newly approved breast cancer drug Kisqali (ribociclib) as a first-line treatment for postmenopausal women with a serious form of the disease.

March 16, 2017 Off

Stada confirms postponing Board bidding session

By Dino Mustafić

Stada’s Supervisory Board has postponed expert sessions which were planned as part of the structured bidding process.

March 16, 2017 Off

Cannabis industry turning into multi-billion dollar opportunity

By Dino Mustafić

In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use. Industry experts forecast the U.S. cannabis market rounding $7 billion in 2016, while the annual sale of state-legal cannabis products is forecast to exceed $20 billion by 2020.

March 16, 2017 Off

Bone Therapeutics reports €13 million net loss for 2016

By Dino Mustafić

Bone Therapeutics, the bone cell therapy company, has reported net loss of €13,02 million for 2016 which is slight decrease in loss comaring to last years €14,07 million net loss.

March 16, 2017 Off

FDA fees for product review would more than double under Trump budget

By Dino Mustafić

The cost to healthcare companies for U.S. regulatory review of their products, including drugs and medical devices, would more than double under the Trump administration’s proposed 2018 budget.